A new and simple blood test has been found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London.
In combination with the current prostate specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment.
Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has a low specificity (high false positives) with about 75 per cent of all PSA positive results ending up with negative biopsies that do not find cancer.
When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and infection. On biopsy, the majority of patients with elevated PSA levels are found not to have cancer.
Additionally, most diagnosed early-stage prostate cancers are not fatal if left untreated. The current practice of the combined PSA test and biopsy for prostate cancer therefore results in unnecessary biopsies and over-diagnosis and overtreatment of many men.
Circulating tumor cells
The new prostate cancer test (the Parsortix® system from ANGLE plc) detects early cancer cells, or circulating tumor cells (CTCs), that have left the original tumour and entered the bloodstream prior to spreading around the body. By measuring intact living cancer cells in the patient’s blood, rather than the PSA protein which may be present in the blood for reasons other than cancer, it potentially provides a more accurate test for prostate cancer.
The study, published in the Journal of Urology, looked at the use of the CTC test in 98 pre-biopsy patients and 155 newly diagnosed prostate cancer patients enrolled at St Bartholomew’s Hospital in London.
The research team found that the presence of CTCs in pre-biopsy blood samples were indicative of the presence of aggressive prostate cancer, and efficiently and non-invasively predicted the later outcome of biopsy results.
When the CTC tests were used in combination with the current PSA test, it was able to predict the presence of aggressive prostate cancer in subsequent biopsies with over 90 per cent accuracy, better than any previously reported biomarkers.
Additionally, the number and type of CTCs present in the blood was also indicative of the aggressiveness of the cancer. Focusing on more aggressive prostate cancer may reduce over-treatment and unnecessary biopsies for benign and non-aggressive conditions.
‘A paradigm shift in the way we diagnose prostate cancer’
Lead researcher Professor Yong-Jie Lu from Queen Mary’s Barts Cancer Institute said: “The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and overtreatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure.
“Testing for circulating tumour cells is efficient, non-invasive and potentially accurate, and we’ve now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer.”
As this is a single centre study, the results need to be further validated in other independent research centres before the CTC test is available either privately or on the NHS in the UK, which could take a further 3-5 years. Clearance by the US Food and Drug Administration could also take 3-5 years.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Circular RNA circ0005276 promotes the proliferation and migration of prostate cancer cells by interacting with FUS to transcriptionally activate XIAPon October 17, 2019 at 7:30 am
Prostate cancer (PCa) is one of the major men’s malignancies with high mortality worldwide. Circular RNAs (circRNAs) have been shown to serve as essential regulators in human cancers. CircRNA can ...
- Tobacco smoking and death from prostate cancer in US veteranson October 17, 2019 at 6:54 am
Cigarette smoking is a risk factor for mortality in several genitourinary cancers, likely due to accumulation of carcinogens in urine. However, in prostate cancer (PC) the link has been less studied.
- U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Is Projected To Reach $389.1 Million By 2026: Grand View Research, Inc.on October 17, 2019 at 4:35 am
Oct 17, 2019 (AB Digital via COMTEX) -- The U.S. prostate cancer nuclear medicine diagnostics market size is expected to reach over USD 389.1 million by 2026 according to a new report by ...
- Prostate Cancer Diagnostics and Minimally Invasive Treatments Markets, 2023on October 17, 2019 at 3:30 am
DUBLIN, Oct. 17, 2019 /PRNewswire/ -- The "Prostate Cancer Diagnostics and Minimally Invasive Treatments Market: US, 5EU Markets, Japan and RoW" report has been added to ResearchAndMarkets.com's ...
- Cleveland Diagnostics receives FDA Breakthrough Device Designation for a prostate cancer diagnostic teston October 16, 2019 at 10:39 am
Cleveland Diagnostics said it has concluded two multicenter clinical trials, led by Cleveland Clinic, in which the diagnostic accuracy of IsoPSA was compared to that of PSA, the current standard of ...
- A precision drug for prostate cancer may slow the disease’s spreadon October 16, 2019 at 4:06 am
A drug used to treat breast and ovarian cancers tied to certain genetic mutations may help combat some of the most severe cases of prostate cancer. Overall in men given olaparib, the disease ...
- For low-risk prostate cancer, active surveillance often beats surgeryon October 16, 2019 at 2:03 am
The most common type of cancer in the United States is prostate cancer, and it is the second-most common cause of cancer deaths in U.S. men behind only lung cancer. According to the National Cancer ...
- MSNBC's Chris Matthews recovering from prostate cancer surgeryon October 15, 2019 at 7:53 am
Longtime "Hardball" host Chris Matthews is recovering from prostate cancer surgery, according to an update on Monday from fill-in host Steve Kornacki on the MSNBC show. "Before we go tonight, Chris ...
- MNSBC 'Hardball': Chris Matthews had prostate cancer surgeryon October 15, 2019 at 7:32 am
On Monday night, Matthews' fill in, Steve Kornacki, shared that Matthews had undergone surgery for prostate cancer and is currently recovering. "Before we go tonight, Chris hasn’t been here the last ...
- Elgin police commander throws himself into raising funds for breast and prostate cancer researchon October 15, 2019 at 2:01 am
Elgin police Cmdr. Jim Bisceglie is excited that his ability to grow a beard is going to raise money for prostate cancer. “I can’t wait,” Bisceglie said about participating in No Shave November. His ...
via Bing News